Ipratropium
Composition
Contains Ipratropium bromide, a short-acting anticholinergic (muscarinic antagonist).
Indications
Used for the maintenance treatment of bronchospasm in chronic obstructive pulmonary disease (COPD) and as an adjunct in asthma.
Side effects
Dry mouth, cough, throat irritation, headache, dizziness.
Precautions
Use with caution in patients with glaucoma, prostatic hyperplasia, or bladder neck obstruction.
Contraindications
Hypersensitivity to ipratropium, atropine, or their derivatives.
Dosage and administration
Inhaler: 2 inhalations 4 times daily; Nebulizer: 500 mcg every 6–8 hours.
Countries
Mexico, Brazil, Colombia
Available Forms
Metered-dose inhaler (MDI), nebulizer solution, combination products with albuterol.